|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Zeng H, Zhang S and He J:
Annual report on status of cancer in China, 2011. Chin J Cancer
Res. 27:2–12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bocanegra A, Fernandez-Hinojal G,
Zuazo-Ibarra M, Arasanz H, Garcia-Granda MJ, Hernandez C, Ibañez M,
Hernandez-Marin B, Martinez-Aguillo M, Lecumberri MJ, et al: PD-L1
expression in systemic immune cell populations as a potential
predictive biomarker of responses to PD-L1/PD-1 blockade therapy in
lung cancer. Int J Mol Sci. 20:pp. E16312019, View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pisani P, Parkin DM, Muñoz N and Ferlay J:
Cancer and infection: Estimates of the attributable fraction in
1990. Cancer Epidemiol Biomarkers Prev. 6:387–400. 1997.PubMed/NCBI
|
|
5
|
Gomes M, Teixeira AL, Coelho A, Araujo A
and Medeiros R: The role of inflammation in lung cancer. Adv Exp
Med Biol. 816:1–23. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Houghton AM, Mouded M and Shapiro SD:
Common origins of lung cancer and COPD. Nat Med. 14:1023–1024.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin TY, Huang WY, Lin JC, Lin CL, Sung FC,
Kao CH and Yeh JJ: Increased lung cancer risk among patients with
pneumococcal pneumonia: A nationwide population-based cohort study.
Lung. 192:159–165. 2014. View Article : Google Scholar
|
|
8
|
De Nardo D: Toll-like receptors:
Activation, signalling and transcriptional modulation. Cytokine.
74:181–189. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He W, Liu Q, Wang L, Chen W, Li N and Cao
X: TLR4 signaling promotes immune escape of human lung cancer cells
by inducing immunosuppressive cytokines and apoptosis resistance.
Mol Immunol. 44:2850–2859. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bauer AK, Upham BL, Rondini EA, Tennis MA,
Velmuragan K and Wiese D: Toll-like receptor expression in human
non-small cell lung carcinoma: Potential prognostic indicators of
disease. Oncotarget. 8:91860–91875. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He J, Hu Y, Hu M and Li B: Development of
PD-1/PD-L1 pathway in tumor immune microenvironment and treatment
for non-small cell lung cancer. Sci Rep. 5:131102015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Johnson DB, Rioth MJ and Horn L: Immune
checkpoint inhibitors in NSCLC. Curr Treat Options Oncol.
15:658–669. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Loke P and Allison JP: PD-L1 and PD-L2 are
differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci
USA. 100:5336–5341. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Beswick EJ, Johnson JR, Saada JI, Humen M,
House J, Dann S, Qiu S, Brasier AR, Powell DW, Reyes VE and Pinchuk
IV: TLR4 activation enhances the PD-L1-mediated tolerogenic
capacity of colonic CD90+ stromal cells. J Immunol. 193:2218–2229.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
16
|
Dudley DT, Pang L, Decker SJ, Bridges AJ
and Saltiel AR: A synthetic inhibitor of the mitogen-activated
protein kinase cascade. Proc Natl Acad Sci USA. 92:7686–7689. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vlahos CJ, Matter WF, Hui KY and Brown RF:
A specific inhibitor of phosphatidylinositol 3-kinase,
2-(4-morpholinyl)- 8-phenyl-4H-1-benzopyran-4-one (LY294002). J
Biol Chem. 269:5241–5248. 1994.PubMed/NCBI
|
|
18
|
Schwartz AG and Cote ML: Epidemiology of
lung cancer. Adv Exp Med Biol. 893:21–41. 2016. View Article : Google Scholar
|
|
19
|
Zhu J, Luo J, Li Y, Jia M, Wang Y, Huang Y
and Ke S: HMGB1 induces human non-small cell lung cancer cell
motility by activating integrin αvβ3/FAK through TLR4/NF-κB
signaling pathway. Biochem Biophys Res Commun. 480:522–527. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dong J, Li B, Lin D, Zhou Q and Huang D:
Advances in targeted therapy and immunotherapy for non-small cell
lung cancer based on accurate molecular typing. Front Pharmacol.
10:2302019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Boeri M, Milione M, Proto C, Signorelli D,
Lo Russo G, Galeone C, Verri C, Mensah M, Centonze G, Martinetti A,
et al: Circulating miRNAs and PD-L1 tumor expression are associated
with survival in advanced NSCLC patients treated with
immunotherapy: A prospective study. Clin Cancer Res. 25:2166–2173.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oikonomopoulou K, Brinc D, Kyriacou K and
Diamandis EP: Infection and cancer: Revaluation of the hygiene
hypothesis. Clin Cancer Res. 19:2834–2841. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jacqueline C, Tasiemski A, Sorci G, Ujvari
B, Maachi F, Missé D, Renaud F, Ewald P, Thomas F and Roche B:
Infections and cancer: The 'fifty shades of immunity' hypothesis.
BMC Cancer. 17:2572017. View Article : Google Scholar
|
|
24
|
Islami F, Chen W, Yu XQ, Lortet-Tieulent
J, Zheng R, Flanders WD, Xia C, Thun MJ, Gapstur SM, Ezzati M and
Jemal A: Cancer deaths and cases attributable to lifestyle factors
and infections in China, 2013. Ann Oncol. 28:2567–2574. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hattori N and Ushijima T: Epigenetic
impact of infection on carcinogenesis: Mechanisms and applications.
Genome Med. 8:102016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ewald PW and Swain Ewald HA: Infection and
cancer in multi-cellular organisms. Philos Trans R Soc Lond B Biol
Sci. 370:pp. 201402242015, View Article : Google Scholar
|
|
27
|
Francescone R, Hou V and Grivennikov SI:
Microbiome, inflammation, and cancer. Cancer J. 20:181–189. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wardak S: Human papillomavirus (HPV) and
cervical cancer. Med Dosw Mikrobiol. 68:73–84. 2016.
|
|
30
|
Denholm R, Schüz J, Straif K, Stücker I,
Jöckel KH, Brenner DR, De Matteis S, Boffetta P, Guida F, Brüske I,
et al: Is previous respiratory disease a risk factor for lung
cancer? Am J Respir Crit Care Med. 190:549–559. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
González I, Araya P and Rojas A:
Helicobacter pylori infection and lung cancer: New insights and
future challenges. Zhongguo Fei Ai Za Zhi. 21:658–662. 2018.
|
|
32
|
Ve T, Vajjhala PR, Hedger A, Croll T,
DiMaio F, Horsefield S, Yu X, Lavrencic P, Hassan Z, Morgan GP, et
al: Structural basis of TIR-domain-assembly formation in MAL- and
MyD88-dependent TLR4 signaling. Nat Struct Mol Biol. 24:743–751.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang B, Zhao J, Li H, He KL, Chen Y, Chen
SH, Mayer L, Unkeless JC and Xiong H: Toll-like receptors on tumor
cells facilitate evasion of immune surveillance. Cancer Res.
65:5009–5014. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hui E, Cheung J, Zhu J, Su X, Taylor MJ,
Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I and Vale RD: T
cell costimulatory receptor CD28 is a primary target for
PD-1-mediated inhibition. Science. 355:1428–1433. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Koyama S, Akbay EA, Li YY, Herter-Sprie
GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ,
Asahina H, et al: Adaptive resistance to therapeutic PD-1 blockade
is associated with upregulation of alternative immune checkpoints.
Nat Commun. 7:105012016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Konen JM, Rodriguez BL, Fradette JJ,
Gibson L, Davis D, Minelli R, Peoples MD, Kovacs J, Carugo A,
Bristow C, et al: Ntrk1 promotes resistance to PD-1 checkpoint
blockade in mesenchymal Kras/p53 mutant lung cancer. Cancers.
11:pp. E4622019, View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Qian Y, Deng J, Geng L, Xie H, Jiang G,
Zhou L, Wang Y, Yin S, Feng X, Liu J, et al: TLR4 signaling induces
B7-H1 expression through MAPK pathways in bladder cancer cells.
Cancer Invest. 26:816–821. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang YH, Cao YW, Yang XC, Niu HT, Sun LJ,
Wang XS and Liu J: Effect of TLR4 and B7-H1 on immune escape of
urothelial bladder cancer and its clinical significance. Asian Pac
J Cancer Prev. 15:1321–1326. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang K, Wang J, Wei F, Zhao N, Yang F and
Ren X: Expression of TLR4 in non-small cell lung cancer is
associated with PD-L1 and poor prognosis in patients receiving
pulmonectomy. Front Immunol. 8:4562017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fleming V, Hu X, Weller C, Weber R, Groth
C, Riester Z, Hüser L, Sun Q, Nagibin V, Kirschning C, et al:
Melanoma extracellular vesicles generate immunosuppressive myeloid
cells by upregulating PD-L1 via TLR4 SIgnaling. Cancer Res.
79:4715–4728. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhao S, Sun M, Meng H, Ji H, Liu Y, Zhang
M, Li H, Li P, Zhang Y and Zhang Q: TLR4 expression correlated with
PD-L1 expression indicates a poor prognosis in patients with
peripheral T-cell lymphomas. Cancer Manag Res. 11:4743–4756. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wei F, Yang F, Li J, Zheng Y, Yu W, Yang L
and Ren X: Soluble Toll-like receptor 4 is a potential serum
biomarker in non-small cell lung cancer. Oncotarget. 7:40106–40114.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hyakushima N, Mitsuzawa H, Nishitani C,
Sano H, Kuronuma K, Konishi M, Himi T, Miyake K and Kuroki Y:
Interaction of soluble form of recombinant extracellular TLR4
domain with MD-2 enables lipopolysaccharide binding and attenuates
TLR4-mediated signaling. J Immunol. 173:6949–6954. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shimazu R, Akashi S, Ogata H, Nagai Y,
Fukudome K, Miyake K and Kimoto M: MD-2, a molecule that confers
lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp
Med. 189:1777–1782. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kuper H, Adami HO and Trichopoulos D:
Infections as a major preventable cause of human cancer. J Intern
Med. 248:171–183. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen CY, Kao CL and Liu CM: The Cancer
prevention, anti-inflammatory and anti-oxidation of bioactive
phytochemicals targeting the TLR4 signaling pathway. Int J Mol Sci.
19:pp. E27292018, View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen CW, Chen CC, Jian CY, Lin PH, Chou
JC, Teng HS, Hu S, Lieu FK, Wang PS and Wang SW: Attenuation of
exercise effect on inflammatory responses via novel role of
TLR4/PI3K/Akt signaling in rat splenocytes. J Appl Physiol (1985).
121:870–877. 2016. View Article : Google Scholar
|
|
50
|
Li H, Xia JQ, Zhu FS, Xi ZH, Pan CY, Gu LM
and Tian YZ: LPS promotes the expression of PD-L1 in gastric cancer
cells through NF-κB activation. J Cell Biochem. 119:9997–10004.
2018. View Article : Google Scholar : PubMed/NCBI
|
